Upfront Briefing
Monday delivered the classic biotech barbell: one brutal single-name unwind, one efficacy narrative quietly losing seven months of shine, and one big-cap finally putting something in the win column. EyePoint's 70% drawdown did most of the talking. Deal flow stayed modest but real, with Lilly putting up to $370M behind OmniAb's ion channel antibodies, Leo paying up to $435M for a Tanabe skin drug already at the FDA, and Slate buying its way onto Nasdaq with $245M in tow. Never a quiet Monday in August.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,745.1 |
(0.5%) |
12.9% |
| Nasdaq 100 |
29,995.4 |
(0.2%) |
19.0% |
| Russell 2000 |
3,057.5 |
(0.4%) |
21.9% |
| Healthcare (XLV) |
167.1 |
(0.2%) |
7.4% |
| Biotech (XBI) |
159.5 |
1.4% |
31.2% |
| Nasdaq Biotech (NBI) |
6,895.5 |
1.4% |
20.8% |
| Clinical Trials (BBC) |
53.3 |
0.7% |
41.5% |
|
- Biotech outran broader healthcare in a clean risk-on session — XBI 1.4%, NBI 1.4% and BBC 0.7% against XLV (0.2%) — with argenx climbing on its Phase 3 Vyvgart Hytrulo win in autoimmune myositis and EyePoint's 70% collapse failing to dent the group.
- The broad tape gave ground after the U.S.–Iran memorandum of understanding expired Monday with no replacement, lifting Brent to $90 and pushing the 30-year Treasury yield above 5.3%, its highest since 2007; the 10-year closed at 4.74% and the VIX rose 5.5% to 16.02.
- Market data: U.S. cash close Monday, 17 August 2026.
The Big 3
|
1
|
EyePoint Phase 3 miss for Duravyu in wet AMD
|
- Duravyu missed the primary endpoint in LUGANO, the first of two Phase 3 wet AMD trials, failing to show non-inferiority to on-label 2mg aflibercept on best-corrected visual acuity at weeks 52 and 56. EyePoint (EYPT) closed down roughly 70%.
- Why it matters: LUGANO missed on best-corrected visual acuity against on-label aflibercept across the full population, and the salvage is an ad hoc cut excluding nine of 211 patients who lost vision for reasons unrelated to wet AMD. Secondaries did land — 42% fewer injections, p<0.0001 — which is the durability case EyePoint has always sold. But durability was never the open question; non-inferiority was. LUCIA in Q4 now carries the entire NDA, targeted for 1H 2027. Jefferies cut its target to $8 and kept the Buy; Mizuho called the primary miss an overhang it cannot dismiss until LUCIA. The cleanest read-through is Ocular Therapeutix, whose axpaxli hit its SOL-1 primary in February.
- Source: Fierce Pharma
- More: BioSpace
|
|
2
|
Ivonescimab benefit narrows with longer follow-up
|
- Ivonescimab showed a smaller progression-free survival benefit with longer follow-up, even as it picked up a third approval in China for first-line patients with certain lung cancers.
- Why it matters: The label the NMPA posted alongside last Wednesday's approval carries roughly seven months more follow-up than the ASCO plenary dataset, and the progression-free survival benefit falls from a 40% risk reduction to 28%. That number is the ex-China thesis: HARMONi-6 was Akeso-run, single-region, against tislelizumab, and Summit still has to reproduce it in HARMONi-3 and HARMONi-7 for the FDA. Leerink flagged increased pessimism while allowing for investor overreaction. A curve that degrades with follow-up is the specific failure mode regulators probe hardest on single-country data, and it lands on top of the COINS Act overhang already sitting on SMMT.
-
Source:
Endpoints
- More: BioSpace
|
| 3 | AstraZeneca finally lands two in lung |
- Phase 3 SAFFRON hit both progression-free and overall survival for Tagrisso plus Orpathys in EGFRm NSCLC with MET amplification after osimertinib, and DESTINY-Lung04 hit its primary PFS endpoint for Enhertu in first-line HER2-mutant non-squamous NSCLC across 454 patients — announced the same morning AstraZeneca stopped eVOLVE-Lung02.
- Why it matters: SAFFRON is the one that pays. Tagrisso plus Orpathys beat platinum chemo on both PFS and OS in EGFR-mutant NSCLC with MET-driven resistance after osimertinib — roughly a third of patients who progress on third-generation EGFR TKIs, and the first all-oral biomarker-directed option in that setting. It extends the Tagrisso annuity past first progression rather than defending it, and takes the HUTCHMED combination global after China's SACHI-based approval. DESTINY-Lung04 adds a first-line PFS win for Enhertu in HER2-mutant disease at n=454. After Wainua, camizestrant and Ultomiris, AstraZeneca needed the late-stage pipeline to print, and the London line closed up 0.9%.
- Source: Endpoints
- More: AstraZeneca; OncLive
|
Everything Else that broke
- Seven drugmakers, PhRMA and BIO backed the USTR's Section 301 probe into Germany's pricing rules, including the proposed 15.5% rebate. — Endpoints
- Phase 3 Vyvgart data supported another label expansion path for Argenx. — BioPharma Dive
- Regeneron stopped an anti-CD3 eye trial after a safety review. — Fierce Biotech
- Sanofi will cut 229 Blueprint employees and close Cambridge offices. — Fierce Pharma
- Celcuity said FDA review of a second Revtorpyk manufacturing site could run two to four months, with shipments still guided to late Q3. — Endpoints
- Merck KGaA cut a further 20 staff from the Massachusetts research site of its EMD Serono division. — Fierce Biotech
- Leo Pharma will pay Tanabe up to $435M in upfront and near-term milestones for worldwide rights to dersimelagon, an oral MC1R agonist under FDA review for erythropoietic protoporphyria. — Fierce Biotech
- Lantheus won FDA approval for Tauklarify, its tau PET imaging agent for Alzheimer's evaluation, on blinded reads of PET images from more than 500 subjects. — Fierce Biotech
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Lilly signed an ion channel antibody collaboration with OmniAb worth up to $370M in milestones, with upfront terms undisclosed. — Fierce Biotech
- Slate Medicines will reverse-merge into Fulcrum Therapeutics alongside a $245M private placement led by Frazier Life Sciences with Forbion, RA Capital and Foresite, taking its DartsBio-licensed anti-PACAP/VIP antibody SLTE-1009 onto Nasdaq with runway into 2029; Fulcrum holders keep 5% plus a cash dividend. — Fierce Biotech
- Leo Pharma licensed worldwide rights to Tanabe's dersimelagon for up to $435M in combined upfront and near-term milestones, plus further milestones and tiered royalties; the oral MC1R agonist was filed with the FDA in June on a Phase 3 win in EPP and XLP, and would compete with Clinuvel's implanted Scenesse. — Fierce Biotech
VC / Private Financings
- Enginprime Medical raised a $12M Series A led by Qiming Venture Partners, with participation from existing and new healthcare investors. — PR
IPOs / Follow-Ons
- No notable IPOs / follow-ons since the last edition. — BioBucks
Academic Corner - Researchers built a scalable platform to discover and characterize substrates of molecular glue degraders. — Nature Biotech
- Virus-like particles enabled targeted gene engineering and pooled CRISPR screening in primary human myeloid cells. — Nature Biotech
|
